CD8A and neoplasm: Thymocyte selection-associated high mobility group box protein (TOX) and P-selectin glycoprotein ligand-1 (PSGL-1) modulate the tumor microenvironment by depleting CD8 + T cells, and they hold promise as targets for tumor immunotherapy6,7.